Lumida
/ANIK
⌘K
Anika Therapeutics Inc

Anika Therapeutics Inc

ANIK
$15.25USD↓-3.60%-0.57 today

MARKET CAP

202.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$15 – $16

52W RANGE

$8
$16

AI Summary

Stalk
Sell NowMedium

ANIK is in a Stage 3 distribution phase, granting bearish medium-term permission. Short-term price is rejecting around the 9/21 EMAs and 50-day SMA, reflecting diminishing demand and structure failure. The preferred execution is selling into rallies near these resistance zones, aligning with the dominant downtrend while respecting potential short-term oversold bounces.

  • ↑Q1 2026 commercial channel revenue grew 12% YoY to $12.6M.
  • ↑Gross margins expanded to 64% from 56% via productivity gains.
  • ↓Q1 OEM channel revenue declined 23% YoY from pricing pressure.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a biotechnology company focused on developing and commercializing innovative regenerative therapies, particularly utilizing hyaluronic acid products in the orthopedic and pain management markets. Anika operates in a competitive landscape, primarily targeting the osteoarthritis (OA) pain management segment. With a commitment to operational excellence, product innovation, and strategic partnerships, Anika aims to leverage its unique technology and established market presence amidst regulatory and competitive challenges.

Bull says

  • ↑Q1 2026 commercial channel revenue grew 12% YoY to $12.6M.
  • ↑Gross margins expanded to 64% from 56% via productivity gains.
  • ↑Ended Q1 with $41M cash and executed $15M buyback.
  • ↑Pipeline includes HylaFAST, supporting future orthopedic revenue growth.
  • ↑Analysts raised earnings and growth revisions, signaling positive sentiment.
  • ↑Full-year revenue guided at $114M–$122.5M, driven by commercial growth.

Bear says

  • ↓Q1 OEM channel revenue declined 23% YoY from pricing pressure.
  • ↓HylaFAST approval faces FDA review delays, risking launch timeline.
  • ↓Negative earnings yield indicates potential overvaluation risk.
  • ↓Manufacturing yield issues strain production capacity and margins.
  • ↓Dependence on J&J for OEM sales limits pricing control.
  • ↓Low institutional ownership and elevated short interest signal downside risk.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • In the first quarter, ANACA generated $29.6 million in total revenue, up 13% year-over-year.
  • Commercial channel revenue grew 12%, reaching $12.6 million, driven by strong international execution and continued momentum and integrity, which continues to exceed our commercial expectations.
  • OEM channel revenue was $17 million in the quarter, representing a 14% increase year-over-year.

Bear points

  • first quarter operating expenses were $24.5 million compared to $19 million in the prior year period.
  • Selling, general, and administrative expenses increased to $17.8 million from $12.9 million a year ago, primarily reflecting $4.9 million of one-time severance-related costs associated with previous announced cost reduction actions.
  • For the OEM channel, we continue to expect revenue to be flat to down approximately 5% year-over-year, or $61 to $64.5 million.
Read full transcript analysis ›